Nuvalent, Inc. - Class A Common Stock (NUVL)

One investor is making a bold bet on Amylyx just as its 2026 catalyst calendar starts to take shape.

This investor just walked away as Scholar Rock heads into a pivotal 2026—here’s what that means for long-term shareholders.

One fast-rising biotech just landed a heavyweight backer ahead of a pivotal presentation—here’s what investors should watch.

Nuvalent shares are trading lower by 6.2% during Tuesday's session. The company priced a $500 million public offering of 5 million shares at $100 each.

Relay’s comeback is gaining momentum—does this latest move signal rising conviction in its pipeline?

Bain Capital sold its entire stake in Nuvalent stock during the third quarter.

Nuvalent reports durable neladalkib responses in pretreated and TKI-naïve ALK-positive NSCLC, with strong rates in the ALKOVE-1 trial.

Nuvalent said Monday almost a third of patients with a hard-to-treat form of lung cancer responded to its experimental drug.

The regular session of the US market on Friday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.

Nuvalent (NUVL) reported Q2 2025 EPS of -$1.31, slightly missing estimates, with no revenue as expected. Shares rose pre-market as investors focus on its oncology pipeline, including zidesamtinib's NDA submission.

Nuvalent releases pivotal ARROS-1 trial data and plans to begin a rolling NDA submission for zidesamtinib in July 2025.

The report covers Nuvectis (NASDAQ: NVCT) alongside notable similar precision oncology players such as Nuvalent ($6.6B) and Summit Therapeutics ($15B).

Federal Reserve's rate cut boosted tech, construction, industrial, machinery, and financial sectors. Top-performing mid-cap stocks last week.

Nuvalent presented updated Phase 1 data from its ARROS-1 and ALKOVE-1 trials at the ESMO Congress 2024. Key data showed promising response rates in pretreated patients, with pivotal results expected in 2025.

Nuvalent and Iteos delivered promising updates in their lung cancer studies. But three patients died in one test.